News

The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.

The decision comes after supporting data from a "mix and match" trial last week, and may align with emergency authorizations for the Moderna and Janssen booster doses.

Merck recently announced results looking at their islatravir implant studied for HIV prevention for 3 months. The long-term goal is to have the implant last 12 months following administration.

Children living with HIV have a new once-daily treatment option to maintain virologic suppression.

One of the infrequently discussed health outcomes that can be impacted by a pandemic is fertility. Using a cross-sectional study, a research team reported incremental increases in infertility during this period.

Lack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.

Comparing 2020 to 2019, investigators saw a reduction in the number of HIV tests, the number of in-person consultations, and new enrollments in care, due to the disruption in HIV care throughout the COVID-19 pandemic.

New survey finds little more than half of US adults are planning to obtain vaccination against influenza despite urging by health officials.

The VRBPAC committee unanimously voted in favor of the Janssen (Johnson & Johnson) COVID-19 vaccine for use under EUA as a booster dose in individuals 18 years and older at least 2 months after a single dose primary vaccination.

Outside of vaccines, these underutilized therapies are the best defense against severe disease.

Lower rates of COVID-19 vaccination may be due to access, not hesitancy.

The VRBPAC meeting precedes deliberation from the FDA on amending the company's emergency authorization to include booster doses for adult patients.

In a recent study, taniborbactam restored in vitro activity of cefepime against Enterobacterales.

While receiving a booster of one’s original COVID-19 shot leads to an immune boost, this was heightened among individuals who received a different booster than their primary vaccine.

There are MSM who are indicated for PrEP use that don’t use it, and vice versa, the study authors found.

The FDA suggested that Johnson & Johnson had not conducted an appropriately thorough test to prove its vaccine requires a six-month booster.

New clinical trial is first to describe concomitant administration of any vaccine with either an adenoviral vector or mRNA COVID-19 vaccine.

CDI remains an urgent public health threat and continues to be the most frequent cause of diarrhea among hospitalized patients and overall hospital-acquired infection in the United States.

People who inject drugs in rural areas had a less accurate understanding of HIV PrEP, largely due to stigma surrounding sexual orientation and drug use.

Investigators found no significant difference among hospitalized patients in the ICU being administered probiotics vs placebo.

A recent study by the CDC found that HIV PrEP awareness and referrals are lower among Hispanic persons than non-Hispanic white persons.

In the recent TACKLE phase 3 trial, AZD7442 significantly reduced the risk of developing severe COVID-19 or death, even among high-risk populations.

No ICU admissions or deaths were reported among Native American patients treated with monoclonal antibodies for COVID-19 in a recent study.

The broad host range and natural reassortment of the influenza virus has played an instrumental role in previous pandemics, and the virus is poised for future large-scale outbreaks.

The filing is for the first oral antiviral therapy, and is based off its phase 3 trial.

The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.

Providers offer their insights on this important topic.

If the FDA approves maribavir, it will be the first and only treatment for adults with CMV as a result of a hematopoietic stem cell transplant or solid organ transplant.